nodes	percent_of_prediction	percent_of_DWPC	metapath
Scopolamine—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0983	0.167	CbGbCtD
Scopolamine—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0889	0.151	CbGbCtD
Scopolamine—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0768	0.131	CbGbCtD
Scopolamine—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0745	0.127	CbGbCtD
Scopolamine—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0674	0.115	CbGbCtD
Scopolamine—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0674	0.115	CbGbCtD
Scopolamine—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0646	0.11	CbGbCtD
Scopolamine—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.05	0.085	CbGbCtD
Scopolamine—SI—digestive system—acquired immunodeficiency syndrome	0.00575	0.118	CbGeAlD
Scopolamine—SI—nervous system—acquired immunodeficiency syndrome	0.00445	0.091	CbGeAlD
Scopolamine—SI—central nervous system—acquired immunodeficiency syndrome	0.00428	0.0876	CbGeAlD
Scopolamine—SI—brain—acquired immunodeficiency syndrome	0.0034	0.0696	CbGeAlD
Scopolamine—CHRM5—skin of body—acquired immunodeficiency syndrome	0.00278	0.0568	CbGeAlD
Scopolamine—CHRM4—nervous system—acquired immunodeficiency syndrome	0.0022	0.0449	CbGeAlD
Scopolamine—CHRM4—central nervous system—acquired immunodeficiency syndrome	0.00212	0.0433	CbGeAlD
Scopolamine—CHRM5—nervous system—acquired immunodeficiency syndrome	0.00172	0.0351	CbGeAlD
Scopolamine—CHRM4—brain—acquired immunodeficiency syndrome	0.00168	0.0344	CbGeAlD
Scopolamine—CHRM5—central nervous system—acquired immunodeficiency syndrome	0.00165	0.0338	CbGeAlD
Scopolamine—CHRM5—brain—acquired immunodeficiency syndrome	0.00131	0.0269	CbGeAlD
Scopolamine—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.00126	0.0257	CbGeAlD
Scopolamine—CHRM3—digestive system—acquired immunodeficiency syndrome	0.00124	0.0254	CbGeAlD
Scopolamine—CHRM2—nervous system—acquired immunodeficiency syndrome	0.00118	0.0241	CbGeAlD
Scopolamine—CHRM1—lung—acquired immunodeficiency syndrome	0.00116	0.0237	CbGeAlD
Scopolamine—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.00113	0.0232	CbGeAlD
Scopolamine—CHRM1—nervous system—acquired immunodeficiency syndrome	0.00107	0.022	CbGeAlD
Scopolamine—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.00103	0.0211	CbGeAlD
Scopolamine—CHRM3—nervous system—acquired immunodeficiency syndrome	0.00096	0.0196	CbGeAlD
Scopolamine—CHRM3—central nervous system—acquired immunodeficiency syndrome	0.000925	0.0189	CbGeAlD
Scopolamine—CHRM2—brain—acquired immunodeficiency syndrome	0.000901	0.0184	CbGeAlD
Scopolamine—CHRM1—brain—acquired immunodeficiency syndrome	0.00082	0.0168	CbGeAlD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Zidovudine—acquired immunodeficiency syndrome	0.000759	0.00228	CcSEcCtD
Scopolamine—Urethral disorder—Saquinavir—acquired immunodeficiency syndrome	0.000756	0.00227	CcSEcCtD
Scopolamine—Erythema—Delavirdine—acquired immunodeficiency syndrome	0.000754	0.00226	CcSEcCtD
Scopolamine—Pruritus—Amprenavir—acquired immunodeficiency syndrome	0.000753	0.00226	CcSEcCtD
Scopolamine—Fatigue—Nevirapine—acquired immunodeficiency syndrome	0.000752	0.00226	CcSEcCtD
Scopolamine—Somnolence—Nelfinavir—acquired immunodeficiency syndrome	0.000751	0.00226	CcSEcCtD
Scopolamine—Vertigo—Indinavir—acquired immunodeficiency syndrome	0.00075	0.00225	CcSEcCtD
Scopolamine—Somnolence—Stavudine—acquired immunodeficiency syndrome	0.000749	0.00225	CcSEcCtD
Scopolamine—Eye disorder—Ritonavir—acquired immunodeficiency syndrome	0.000749	0.00225	CcSEcCtD
Scopolamine—Pain—Nevirapine—acquired immunodeficiency syndrome	0.000746	0.00224	CcSEcCtD
Scopolamine—Flushing—Ritonavir—acquired immunodeficiency syndrome	0.000744	0.00223	CcSEcCtD
Scopolamine—Visual impairment—Saquinavir—acquired immunodeficiency syndrome	0.000743	0.00223	CcSEcCtD
Scopolamine—Vision blurred—Efavirenz—acquired immunodeficiency syndrome	0.000743	0.00223	CcSEcCtD
Scopolamine—Tremor—Efavirenz—acquired immunodeficiency syndrome	0.000739	0.00222	CcSEcCtD
Scopolamine—Confusional state—Zidovudine—acquired immunodeficiency syndrome	0.000738	0.00222	CcSEcCtD
Scopolamine—CHRM3—brain—acquired immunodeficiency syndrome	0.000734	0.015	CbGeAlD
Scopolamine—Oedema—Zidovudine—acquired immunodeficiency syndrome	0.000732	0.0022	CcSEcCtD
Scopolamine—Pharyngitis—Lamivudine—acquired immunodeficiency syndrome	0.00073	0.00219	CcSEcCtD
Scopolamine—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000726	0.00218	CcSEcCtD
Scopolamine—Agitation—Efavirenz—acquired immunodeficiency syndrome	0.000724	0.00217	CcSEcCtD
Scopolamine—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000723	0.00217	CcSEcCtD
Scopolamine—Eye disorder—Saquinavir—acquired immunodeficiency syndrome	0.000721	0.00216	CcSEcCtD
Scopolamine—Constipation—Stavudine—acquired immunodeficiency syndrome	0.00072	0.00216	CcSEcCtD
Scopolamine—Pain—Stavudine—acquired immunodeficiency syndrome	0.00072	0.00216	CcSEcCtD
Scopolamine—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.000719	0.00216	CcSEcCtD
Scopolamine—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000718	0.00216	CcSEcCtD
Scopolamine—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000716	0.00215	CcSEcCtD
Scopolamine—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000711	0.00213	CcSEcCtD
Scopolamine—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.000711	0.00213	CcSEcCtD
Scopolamine—Pain—Abacavir—acquired immunodeficiency syndrome	0.00071	0.00213	CcSEcCtD
Scopolamine—Vertigo—Efavirenz—acquired immunodeficiency syndrome	0.000708	0.00213	CcSEcCtD
Scopolamine—Hyperhidrosis—Zidovudine—acquired immunodeficiency syndrome	0.000708	0.00212	CcSEcCtD
Scopolamine—Tremor—Delavirdine—acquired immunodeficiency syndrome	0.000707	0.00212	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000705	0.00212	CcSEcCtD
Scopolamine—Mental disorder—Ritonavir—acquired immunodeficiency syndrome	0.000702	0.00211	CcSEcCtD
Scopolamine—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.000696	0.00209	CcSEcCtD
Scopolamine—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000696	0.00209	CcSEcCtD
Scopolamine—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000695	0.00209	CcSEcCtD
Scopolamine—Agitation—Delavirdine—acquired immunodeficiency syndrome	0.000693	0.00208	CcSEcCtD
Scopolamine—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.00069	0.00207	CcSEcCtD
Scopolamine—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.00069	0.00207	CcSEcCtD
Scopolamine—ABCB1—retina—acquired immunodeficiency syndrome	0.000688	0.0141	CbGeAlD
Scopolamine—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000687	0.00206	CcSEcCtD
Scopolamine—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.000684	0.00205	CcSEcCtD
Scopolamine—Oedema—Indinavir—acquired immunodeficiency syndrome	0.000681	0.00204	CcSEcCtD
Scopolamine—Vertigo—Delavirdine—acquired immunodeficiency syndrome	0.000678	0.00203	CcSEcCtD
Scopolamine—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000677	0.00203	CcSEcCtD
Scopolamine—Mental disorder—Saquinavir—acquired immunodeficiency syndrome	0.000676	0.00203	CcSEcCtD
Scopolamine—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.000671	0.00202	CcSEcCtD
Scopolamine—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000671	0.00201	CcSEcCtD
Scopolamine—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000671	0.00201	CcSEcCtD
Scopolamine—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000668	0.00201	CcSEcCtD
Scopolamine—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000668	0.00201	CcSEcCtD
Scopolamine—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000668	0.002	CcSEcCtD
Scopolamine—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000667	0.002	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000667	0.002	CcSEcCtD
Scopolamine—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000666	0.002	CcSEcCtD
Scopolamine—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000666	0.002	CcSEcCtD
Scopolamine—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000661	0.00199	CcSEcCtD
Scopolamine—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000658	0.00198	CcSEcCtD
Scopolamine—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.000657	0.00197	CcSEcCtD
Scopolamine—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000656	0.00197	CcSEcCtD
Scopolamine—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000656	0.00197	CcSEcCtD
Scopolamine—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000656	0.00197	CcSEcCtD
Scopolamine—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000654	0.00196	CcSEcCtD
Scopolamine—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000651	0.00195	CcSEcCtD
Scopolamine—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.000649	0.00195	CcSEcCtD
Scopolamine—Agitation—Ritonavir—acquired immunodeficiency syndrome	0.000641	0.00192	CcSEcCtD
Scopolamine—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.00064	0.00192	CcSEcCtD
Scopolamine—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000632	0.0019	CcSEcCtD
Scopolamine—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000631	0.00189	CcSEcCtD
Scopolamine—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000631	0.00189	CcSEcCtD
Scopolamine—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000629	0.00189	CcSEcCtD
Scopolamine—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000628	0.00189	CcSEcCtD
Scopolamine—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.000628	0.00188	CcSEcCtD
Scopolamine—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.000627	0.00188	CcSEcCtD
Scopolamine—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000626	0.00188	CcSEcCtD
Scopolamine—Pain—Zidovudine—acquired immunodeficiency syndrome	0.000626	0.00188	CcSEcCtD
Scopolamine—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000626	0.00188	CcSEcCtD
Scopolamine—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000625	0.00188	CcSEcCtD
Scopolamine—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000622	0.00187	CcSEcCtD
Scopolamine—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.000621	0.00186	CcSEcCtD
Scopolamine—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000617	0.00185	CcSEcCtD
Scopolamine—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000617	0.00185	CcSEcCtD
Scopolamine—Agitation—Saquinavir—acquired immunodeficiency syndrome	0.000617	0.00185	CcSEcCtD
Scopolamine—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000616	0.00185	CcSEcCtD
Scopolamine—Rash—Didanosine—acquired immunodeficiency syndrome	0.000612	0.00184	CcSEcCtD
Scopolamine—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000611	0.00183	CcSEcCtD
Scopolamine—Headache—Didanosine—acquired immunodeficiency syndrome	0.000608	0.00182	CcSEcCtD
Scopolamine—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000606	0.00182	CcSEcCtD
Scopolamine—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000605	0.00182	CcSEcCtD
Scopolamine—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000604	0.00181	CcSEcCtD
Scopolamine—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.000603	0.00181	CcSEcCtD
Scopolamine—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.000603	0.00181	CcSEcCtD
Scopolamine—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.000601	0.0018	CcSEcCtD
Scopolamine—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.0006	0.0018	CcSEcCtD
Scopolamine—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000598	0.00179	CcSEcCtD
Scopolamine—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000598	0.00179	CcSEcCtD
Scopolamine—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000596	0.00179	CcSEcCtD
Scopolamine—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000595	0.00179	CcSEcCtD
Scopolamine—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000595	0.00179	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.00059	0.00177	CcSEcCtD
Scopolamine—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000587	0.00176	CcSEcCtD
Scopolamine—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000587	0.00176	CcSEcCtD
Scopolamine—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000582	0.00175	CcSEcCtD
Scopolamine—Pain—Indinavir—acquired immunodeficiency syndrome	0.000582	0.00175	CcSEcCtD
Scopolamine—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000581	0.00174	CcSEcCtD
Scopolamine—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000579	0.00174	CcSEcCtD
Scopolamine—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000579	0.00174	CcSEcCtD
Scopolamine—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000576	0.00173	CcSEcCtD
Scopolamine—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.000575	0.00173	CcSEcCtD
Scopolamine—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000575	0.00173	CcSEcCtD
Scopolamine—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.000574	0.00172	CcSEcCtD
Scopolamine—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000572	0.00172	CcSEcCtD
Scopolamine—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000569	0.00171	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000568	0.0017	CcSEcCtD
Scopolamine—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.000561	0.00168	CcSEcCtD
Scopolamine—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000559	0.00168	CcSEcCtD
Scopolamine—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000559	0.00168	CcSEcCtD
Scopolamine—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000558	0.00168	CcSEcCtD
Scopolamine—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000557	0.00167	CcSEcCtD
Scopolamine—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.000556	0.00167	CcSEcCtD
Scopolamine—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000555	0.00167	CcSEcCtD
Scopolamine—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000555	0.00167	CcSEcCtD
Scopolamine—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000553	0.00166	CcSEcCtD
Scopolamine—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.000552	0.00166	CcSEcCtD
Scopolamine—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.00055	0.00165	CcSEcCtD
Scopolamine—Pain—Efavirenz—acquired immunodeficiency syndrome	0.00055	0.00165	CcSEcCtD
Scopolamine—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.00055	0.00165	CcSEcCtD
Scopolamine—Rash—Nevirapine—acquired immunodeficiency syndrome	0.00055	0.00165	CcSEcCtD
Scopolamine—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.00055	0.00165	CcSEcCtD
Scopolamine—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000549	0.00165	CcSEcCtD
Scopolamine—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000548	0.00164	CcSEcCtD
Scopolamine—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000547	0.00164	CcSEcCtD
Scopolamine—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000547	0.00164	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000542	0.00163	CcSEcCtD
Scopolamine—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000538	0.00162	CcSEcCtD
Scopolamine—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000538	0.00162	CcSEcCtD
Scopolamine—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000537	0.00161	CcSEcCtD
Scopolamine—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000537	0.00161	CcSEcCtD
Scopolamine—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000536	0.00161	CcSEcCtD
Scopolamine—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000533	0.0016	CcSEcCtD
Scopolamine—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000533	0.0016	CcSEcCtD
Scopolamine—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000532	0.0016	CcSEcCtD
Scopolamine—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000532	0.0016	CcSEcCtD
Scopolamine—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000532	0.0016	CcSEcCtD
Scopolamine—Rash—Stavudine—acquired immunodeficiency syndrome	0.000531	0.00159	CcSEcCtD
Scopolamine—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000531	0.00159	CcSEcCtD
Scopolamine—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000531	0.00159	CcSEcCtD
Scopolamine—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.00053	0.00159	CcSEcCtD
Scopolamine—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.00053	0.00159	CcSEcCtD
Scopolamine—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000529	0.00159	CcSEcCtD
Scopolamine—Headache—Stavudine—acquired immunodeficiency syndrome	0.000528	0.00158	CcSEcCtD
Scopolamine—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000528	0.00158	CcSEcCtD
Scopolamine—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.000527	0.00158	CcSEcCtD
Scopolamine—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000526	0.00158	CcSEcCtD
Scopolamine—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000526	0.00158	CcSEcCtD
Scopolamine—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000525	0.00158	CcSEcCtD
Scopolamine—Rash—Abacavir—acquired immunodeficiency syndrome	0.000523	0.00157	CcSEcCtD
Scopolamine—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000523	0.00157	CcSEcCtD
Scopolamine—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000523	0.00157	CcSEcCtD
Scopolamine—Headache—Abacavir—acquired immunodeficiency syndrome	0.00052	0.00156	CcSEcCtD
Scopolamine—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000518	0.00156	CcSEcCtD
Scopolamine—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000518	0.00156	CcSEcCtD
Scopolamine—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000513	0.00154	CcSEcCtD
Scopolamine—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.000512	0.00154	CcSEcCtD
Scopolamine—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000509	0.00153	CcSEcCtD
Scopolamine—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000509	0.00153	CcSEcCtD
Scopolamine—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000508	0.00152	CcSEcCtD
Scopolamine—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.000507	0.00152	CcSEcCtD
Scopolamine—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000506	0.00152	CcSEcCtD
Scopolamine—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000505	0.00152	CcSEcCtD
Scopolamine—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000502	0.00151	CcSEcCtD
Scopolamine—Nausea—Stavudine—acquired immunodeficiency syndrome	0.0005	0.0015	CcSEcCtD
Scopolamine—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000493	0.00148	CcSEcCtD
Scopolamine—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000491	0.00147	CcSEcCtD
Scopolamine—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000489	0.01	CbGeAlD
Scopolamine—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000489	0.00147	CcSEcCtD
Scopolamine—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000488	0.00147	CcSEcCtD
Scopolamine—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000487	0.00146	CcSEcCtD
Scopolamine—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000487	0.00146	CcSEcCtD
Scopolamine—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000487	0.00146	CcSEcCtD
Scopolamine—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000487	0.00146	CcSEcCtD
Scopolamine—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000487	0.00146	CcSEcCtD
Scopolamine—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000484	0.00145	CcSEcCtD
Scopolamine—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000483	0.00988	CbGeAlD
Scopolamine—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000482	0.00145	CcSEcCtD
Scopolamine—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000472	0.00142	CcSEcCtD
Scopolamine—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.000469	0.00141	CcSEcCtD
Scopolamine—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000469	0.00141	CcSEcCtD
Scopolamine—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000469	0.00141	CcSEcCtD
Scopolamine—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000466	0.0014	CcSEcCtD
Scopolamine—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000465	0.00139	CcSEcCtD
Scopolamine—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000462	0.00139	CcSEcCtD
Scopolamine—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000462	0.00139	CcSEcCtD
Scopolamine—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000461	0.00138	CcSEcCtD
Scopolamine—ABCB1—blood—acquired immunodeficiency syndrome	0.00046	0.00941	CbGeAlD
Scopolamine—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000459	0.00138	CcSEcCtD
Scopolamine—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000455	0.00137	CcSEcCtD
Scopolamine—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.000452	0.00136	CcSEcCtD
Scopolamine—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000451	0.00135	CcSEcCtD
Scopolamine—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00045	0.00135	CcSEcCtD
Scopolamine—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.00045	0.00135	CcSEcCtD
Scopolamine—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.00045	0.00135	CcSEcCtD
Scopolamine—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000447	0.00134	CcSEcCtD
Scopolamine—Pain—Lamivudine—acquired immunodeficiency syndrome	0.000447	0.00134	CcSEcCtD
Scopolamine—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000445	0.00911	CbGeAlD
Scopolamine—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000443	0.00907	CbGeAlD
Scopolamine—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000442	0.00133	CcSEcCtD
Scopolamine—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000436	0.00131	CcSEcCtD
Scopolamine—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000435	0.00131	CcSEcCtD
Scopolamine—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000433	0.0013	CcSEcCtD
Scopolamine—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000433	0.0013	CcSEcCtD
Scopolamine—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000433	0.0013	CcSEcCtD
Scopolamine—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.000431	0.00129	CcSEcCtD
Scopolamine—Rash—Indinavir—acquired immunodeficiency syndrome	0.000429	0.00129	CcSEcCtD
Scopolamine—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000429	0.00129	CcSEcCtD
Scopolamine—Headache—Indinavir—acquired immunodeficiency syndrome	0.000427	0.00128	CcSEcCtD
Scopolamine—ABCB1—vagina—acquired immunodeficiency syndrome	0.000427	0.00872	CbGeAlD
Scopolamine—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000425	0.00128	CcSEcCtD
Scopolamine—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000413	0.00124	CcSEcCtD
Scopolamine—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000413	0.00124	CcSEcCtD
Scopolamine—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000409	0.00123	CcSEcCtD
Scopolamine—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000408	0.00123	CcSEcCtD
Scopolamine—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000407	0.00122	CcSEcCtD
Scopolamine—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000406	0.00122	CcSEcCtD
Scopolamine—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000405	0.00122	CcSEcCtD
Scopolamine—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000404	0.00121	CcSEcCtD
Scopolamine—ABCB1—lung—acquired immunodeficiency syndrome	0.000403	0.00825	CbGeAlD
Scopolamine—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000403	0.00121	CcSEcCtD
Scopolamine—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000403	0.00121	CcSEcCtD
Scopolamine—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000393	0.00118	CcSEcCtD
Scopolamine—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000391	0.00117	CcSEcCtD
Scopolamine—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000388	0.00117	CcSEcCtD
Scopolamine—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000388	0.00116	CcSEcCtD
Scopolamine—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000388	0.00116	CcSEcCtD
Scopolamine—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000386	0.00116	CcSEcCtD
Scopolamine—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000382	0.00115	CcSEcCtD
Scopolamine—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000376	0.00113	CcSEcCtD
Scopolamine—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000375	0.00113	CcSEcCtD
Scopolamine—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000374	0.00764	CbGeAlD
Scopolamine—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.00037	0.00111	CcSEcCtD
Scopolamine—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000366	0.0011	CcSEcCtD
Scopolamine—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000362	0.00109	CcSEcCtD
Scopolamine—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000362	0.00109	CcSEcCtD
Scopolamine—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.00036	0.00736	CbGeAlD
Scopolamine—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000359	0.00108	CcSEcCtD
Scopolamine—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000359	0.00108	CcSEcCtD
Scopolamine—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000357	0.00107	CcSEcCtD
Scopolamine—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000348	0.00105	CcSEcCtD
Scopolamine—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000346	0.00104	CcSEcCtD
Scopolamine—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000345	0.00104	CcSEcCtD
Scopolamine—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000345	0.00104	CcSEcCtD
Scopolamine—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000343	0.00103	CcSEcCtD
Scopolamine—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000338	0.00102	CcSEcCtD
Scopolamine—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000332	0.000998	CcSEcCtD
Scopolamine—Rash—Lamivudine—acquired immunodeficiency syndrome	0.00033	0.000989	CcSEcCtD
Scopolamine—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000329	0.000988	CcSEcCtD
Scopolamine—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000327	0.000983	CcSEcCtD
Scopolamine—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000325	0.000977	CcSEcCtD
Scopolamine—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00031	0.000932	CcSEcCtD
Scopolamine—ABCB1—brain—acquired immunodeficiency syndrome	0.000286	0.00584	CbGeAlD
Scopolamine—ABCB1—lymph node—acquired immunodeficiency syndrome	0.000276	0.00564	CbGeAlD
Scopolamine—CHRM2—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000128	0.00425	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000127	0.00422	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000127	0.00421	CbGpPWpGaD
Scopolamine—CHRM2—SIDS Susceptibility Pathways—IL10—acquired immunodeficiency syndrome	0.000126	0.00421	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000125	0.00417	CbGpPWpGaD
Scopolamine—CHRM4—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000124	0.00412	CbGpPWpGaD
Scopolamine—CHRM5—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000123	0.0041	CbGpPWpGaD
Scopolamine—CHRM2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.00012	0.004	CbGpPWpGaD
Scopolamine—CHRM2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.00012	0.004	CbGpPWpGaD
Scopolamine—CHRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00012	0.004	CbGpPWpGaD
Scopolamine—CHRM3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00012	0.00399	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000119	0.00396	CbGpPWpGaD
Scopolamine—CHRM2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000119	0.00395	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000119	0.00394	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000117	0.0039	CbGpPWpGaD
Scopolamine—CHRM4—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000116	0.00387	CbGpPWpGaD
Scopolamine—CHRM4—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000115	0.00382	CbGpPWpGaD
Scopolamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000114	0.00379	CbGpPWpGaD
Scopolamine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000114	0.00378	CbGpPWpGaD
Scopolamine—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000113	0.00376	CbGpPWpGaD
Scopolamine—CHRM3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000113	0.00375	CbGpPWpGaD
Scopolamine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000112	0.00374	CbGpPWpGaD
Scopolamine—CHRM2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000112	0.00371	CbGpPWpGaD
Scopolamine—CHRM5—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000111	0.00371	CbGpPWpGaD
Scopolamine—CHRM5—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00011	0.00366	CbGpPWpGaD
Scopolamine—CHRM4—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000109	0.00364	CbGpPWpGaD
Scopolamine—CHRM4—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000109	0.00364	CbGpPWpGaD
Scopolamine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000109	0.00363	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000107	0.00355	CbGpPWpGaD
Scopolamine—CHRM5—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000105	0.00348	CbGpPWpGaD
Scopolamine—CHRM5—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000105	0.00348	CbGpPWpGaD
Scopolamine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000105	0.00348	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000104	0.00347	CbGpPWpGaD
Scopolamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000103	0.00343	CbGpPWpGaD
Scopolamine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000103	0.00342	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000102	0.0034	CbGpPWpGaD
Scopolamine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000102	0.00338	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	9.98e-05	0.00332	CbGpPWpGaD
Scopolamine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	9.84e-05	0.00327	CbGpPWpGaD
Scopolamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	9.68e-05	0.00322	CbGpPWpGaD
Scopolamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	9.68e-05	0.00322	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	9.66e-05	0.00321	CbGpPWpGaD
Scopolamine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	9.65e-05	0.00321	CbGpPWpGaD
Scopolamine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	9.65e-05	0.00321	CbGpPWpGaD
Scopolamine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	9.56e-05	0.00318	CbGpPWpGaD
Scopolamine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	9.56e-05	0.00318	CbGpPWpGaD
Scopolamine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	9.43e-05	0.00314	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	9.25e-05	0.00308	CbGpPWpGaD
Scopolamine—CHRM2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	9.15e-05	0.00304	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	8.67e-05	0.00289	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	8.65e-05	0.00288	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	8.56e-05	0.00285	CbGpPWpGaD
Scopolamine—SI—Disease—CD4—acquired immunodeficiency syndrome	8.45e-05	0.00281	CbGpPWpGaD
Scopolamine—CHRM4—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	8.32e-05	0.00277	CbGpPWpGaD
Scopolamine—CHRM2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	8.24e-05	0.00274	CbGpPWpGaD
Scopolamine—ABCB1—Allograft Rejection—IFNG—acquired immunodeficiency syndrome	8.21e-05	0.00273	CbGpPWpGaD
Scopolamine—SI—Metabolism—ALB—acquired immunodeficiency syndrome	8.03e-05	0.00267	CbGpPWpGaD
Scopolamine—CHRM5—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	7.97e-05	0.00265	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.84e-05	0.00261	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.82e-05	0.0026	CbGpPWpGaD
Scopolamine—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.75e-05	0.00258	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	7.74e-05	0.00258	CbGpPWpGaD
Scopolamine—CHRM3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.72e-05	0.00257	CbGpPWpGaD
Scopolamine—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	7.65e-05	0.00254	CbGpPWpGaD
Scopolamine—CHRM4—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	7.5e-05	0.00249	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—TAT—acquired immunodeficiency syndrome	7.46e-05	0.00248	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.37e-05	0.00245	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.37e-05	0.00245	CbGpPWpGaD
Scopolamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.37e-05	0.00245	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.35e-05	0.00245	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.35e-05	0.00245	CbGpPWpGaD
Scopolamine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.34e-05	0.00244	CbGpPWpGaD
Scopolamine—ABCB1—Allograft Rejection—IL2—acquired immunodeficiency syndrome	7.3e-05	0.00243	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	7.28e-05	0.00242	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	7.28e-05	0.00242	CbGpPWpGaD
Scopolamine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	7.27e-05	0.00242	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.2e-05	0.0024	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.18e-05	0.00239	CbGpPWpGaD
Scopolamine—CHRM5—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	7.18e-05	0.00239	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	7.11e-05	0.00237	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7.02e-05	0.00234	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	7e-05	0.00233	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	6.93e-05	0.00231	CbGpPWpGaD
Scopolamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.64e-05	0.00221	CbGpPWpGaD
Scopolamine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.62e-05	0.0022	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	6.6e-05	0.0022	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	6.57e-05	0.00219	CbGpPWpGaD
Scopolamine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	6.55e-05	0.00218	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.52e-05	0.00217	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.49e-05	0.00216	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	6.43e-05	0.00214	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—AGPS—acquired immunodeficiency syndrome	6.35e-05	0.00211	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	6.32e-05	0.0021	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.31e-05	0.0021	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.31e-05	0.0021	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	6.3e-05	0.00209	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	6.18e-05	0.00206	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	6.18e-05	0.00206	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	6.04e-05	0.00201	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	6.04e-05	0.00201	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.97e-05	0.00199	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	5.92e-05	0.00197	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	5.92e-05	0.00197	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	5.72e-05	0.0019	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.71e-05	0.0019	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.61e-05	0.00187	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.61e-05	0.00187	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.61e-05	0.00187	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.59e-05	0.00186	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	5.54e-05	0.00184	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	5.47e-05	0.00182	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	5.37e-05	0.00179	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	5.37e-05	0.00179	CbGpPWpGaD
Scopolamine—ABCB1—Allograft Rejection—TNF—acquired immunodeficiency syndrome	5.31e-05	0.00177	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.05e-05	0.00168	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	5.04e-05	0.00168	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	4.99e-05	0.00166	CbGpPWpGaD
Scopolamine—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	4.81e-05	0.0016	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—TAT—acquired immunodeficiency syndrome	4.74e-05	0.00158	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.7e-05	0.00156	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.63e-05	0.00154	CbGpPWpGaD
Scopolamine—SI—Disease—IL6—acquired immunodeficiency syndrome	4.57e-05	0.00152	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	4.5e-05	0.0015	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.45e-05	0.00148	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.44e-05	0.00148	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	4.44e-05	0.00148	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.43e-05	0.00147	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.42e-05	0.00147	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	4.39e-05	0.00146	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	4.38e-05	0.00146	CbGpPWpGaD
Scopolamine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	4.32e-05	0.00144	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.27e-05	0.00142	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.26e-05	0.00142	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.26e-05	0.00142	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.24e-05	0.00141	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.24e-05	0.00141	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.24e-05	0.00141	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.21e-05	0.0014	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	4.2e-05	0.0014	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	4.2e-05	0.0014	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.17e-05	0.00139	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.17e-05	0.00139	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.15e-05	0.00138	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.15e-05	0.00138	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	4.11e-05	0.00137	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	4.11e-05	0.00137	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.09e-05	0.00136	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.06e-05	0.00135	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.03e-05	0.00134	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	4.03e-05	0.00134	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.03e-05	0.00134	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	4.01e-05	0.00133	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	3.97e-05	0.00132	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.9e-05	0.0013	CbGpPWpGaD
Scopolamine—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	3.88e-05	0.00129	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.85e-05	0.00128	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.85e-05	0.00128	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.84e-05	0.00128	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	3.8e-05	0.00126	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.78e-05	0.00126	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.78e-05	0.00126	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.77e-05	0.00125	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.77e-05	0.00125	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	3.74e-05	0.00124	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	3.74e-05	0.00124	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.73e-05	0.00124	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.68e-05	0.00123	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.53e-05	0.00117	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	3.38e-05	0.00112	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.32e-05	0.0011	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.32e-05	0.0011	CbGpPWpGaD
Scopolamine—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	3.21e-05	0.00107	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.18e-05	0.00106	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.18e-05	0.00106	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.17e-05	0.00105	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.16e-05	0.00105	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.13e-05	0.00104	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.12e-05	0.00104	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.11e-05	0.00104	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.08e-05	0.00103	CbGpPWpGaD
Scopolamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.04e-05	0.00101	CbGpPWpGaD
Scopolamine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	3.03e-05	0.00101	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.88e-05	0.000958	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.87e-05	0.000955	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.86e-05	0.00095	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.85e-05	0.000947	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.84e-05	0.000945	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.84e-05	0.000943	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.83e-05	0.00094	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.82e-05	0.000938	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.8e-05	0.000931	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.63e-05	0.000875	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	2.62e-05	0.000873	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.62e-05	0.000872	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.6e-05	0.000863	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.59e-05	0.000863	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.59e-05	0.00086	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.56e-05	0.000852	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.52e-05	0.000839	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.48e-05	0.000827	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.45e-05	0.000814	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.42e-05	0.000804	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.38e-05	0.000792	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.38e-05	0.000791	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.37e-05	0.000788	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.35e-05	0.000781	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.34e-05	0.00078	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.27e-05	0.000756	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.24e-05	0.000744	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.24e-05	0.000744	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.23e-05	0.000741	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.23e-05	0.000741	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.22e-05	0.000739	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.21e-05	0.000734	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.21e-05	0.000734	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.18e-05	0.000724	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.13e-05	0.000708	CbGpPWpGaD
Scopolamine—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.76e-05	0.000587	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.7e-05	0.000566	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.7e-05	0.000564	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.68e-05	0.000559	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.68e-05	0.000557	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.67e-05	0.000556	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.65e-05	0.00055	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.65e-05	0.000549	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.65e-05	0.000547	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.63e-05	0.000542	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.53e-05	0.00051	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.53e-05	0.000508	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.51e-05	0.000503	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.5e-05	0.000499	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.49e-05	0.000497	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.48e-05	0.000492	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.31e-05	0.000437	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.31e-05	0.000435	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—ALB—acquired immunodeficiency syndrome	1.3e-05	0.000433	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.26e-05	0.000418	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.25e-05	0.000416	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.85e-06	0.000295	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.82e-06	0.000294	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.81e-06	0.000293	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.78e-06	0.000292	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.74e-06	0.000291	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.7e-06	0.000289	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	8.26e-06	0.000275	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.72e-06	0.000257	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.39e-06	0.000246	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.2e-06	0.000173	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.19e-06	0.000173	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.14e-06	0.000171	CbGpPWpGaD
